Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 126

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 126
---
 registration statement on Form S-3 and increase our transaction costs, and could, to the extent we are not able to conduct
offerings using alternative methods, adversely impact our liquidity, ability to raise capital or complete acquisitions in a timely manner.
The use of Form S-1 would also prevent us from conducting offerings on a “shelf basis,” limiting our flexibility as to the
terms, timing or manner of any such offering.

We cannot guarantee that
in the future our reporting will always be timely. If we are unable to satisfy SEC filing deadlines or otherwise provide disclosures
of material information on a timely basis, stockholders and potential investors in our Common Stock may have incomplete information about
our business and results of operations, which may impact their ability to make an informed investment decision, result in a reduction
in the trading price, trading volume or analyst coverage of our Common Stock or expose us to potential liability.

We could be subject to securities class action litigation.

In the past, securities
class action litigation has often been brought against a company following a decline in the market price of its securities. This risk
is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years.
If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which
could harm our business.

Any such negative outcome
could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our business practices. Defending
against litigation is costly and time-consuming, and could divert management’s attention and our resources. Furthermore, during
the course of litigation, there could be negative public announcements of the results of hearings, motions or other interim proceedings
or developments, which could have a negative effect on the market price of our Common Stock.

Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of its securities.

On July 19, 2024, we received
the Bid Price Requirement Letter from the staff at Nasdaq notifying us that, for the 30 consecutive trading days prior to the date of
the Bid Price Requirement Letter, the closing bid price for the Common Stock has been below the minimum $1.00 per share required for
continued listing on Nasdaq set forth in Nasdaq Listing Rule 450(a)(1), which is required for continued listing of the Common Stock on
Nasdaq (the “Bid Price Requirement”). On October 23, 2024, the trading price for our Common Stock closed